Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Aytu BioPharma, Inc. (AYTU)

1.1100
+0.0100
+(0.91%)
At close: April 25 at 4:00:00 PM EDT
1.0600
-0.05
(-4.50%)
After hours: April 25 at 5:15:11 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Joshua R. Disbrow CEO & Director 873.2k -- 1975
Mr. Jarrett T. Disbrow Ph.D. Chief Business Officer 531.09k -- 1975
Mr. Greg Pyszczymuka Chief Commercial Officer 505.3k -- 1980
Mr. Ryan J. Selhorn CPA CFO, Corporate Secretary & Treasurer -- -- 1982
Ms. Margaret Cabano Vice President of Operations -- -- --

Aytu BioPharma, Inc.

Denver Corporate Center III
Suite 920 7900 East Union Avenue
Denver, CO 80237
United States
(720) 437-6580 https://aytubio.com
Sector: 
Healthcare
Full Time Employees: 
102

Description

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Corporate Governance

Aytu BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 13, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC

Aytu BioPharma, Inc. Earnings Date

Recent Events

March 28, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

February 12, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

December 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 11, 2024 at 12:00 AM UTC

S-3/A: Offering Registrations

October 7, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

October 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers